Sickle Cell Disease Treatment Market Size, Share and Growth Analysis 2030
2022 年镰状细胞病治疗市场价值为 11.6016 亿美元,预计到 2030 年将达到 46.9187 亿美元;预计 2022 年至 2030 年的复合年增长率为 19.1%。
市场洞察和分析师观点:
镰状细胞性贫血是一组影响血红蛋白的疾病,血红蛋白是一种将氧气输送到全身组织和器官的分子。当这种疾病发生时,红细胞会呈现新月形或月牙形,患者会患上贫血症。镰状细胞病 (SCD) 是一种遗传性疾病,可以用药物治疗以控制症状和姑息治疗。输血、骨髓移植和药物是最常见的治疗选择。虽然骨髓移植是唯一可能治愈的治疗方法,但它只推荐给有限比例的患者。市场上只有两种 FDA 批准的药物:羟基脲和 Endari。
各国政府和私人组织为治疗这种疾病而采取的举措越来越多,预计将在未来几年推动镰状细胞病治疗市场的发展。例如,根据世卫组织 2022 年 8 月发布的数据,一些非洲卫生部长发起了一项运动,以提高认识并加强预防和护理,以降低镰状细胞性贫血的发病率,镰状细胞性贫血是该地区最常见的疾病之一,但并未得到足够的重视。消息人士还表示,全球 1.2 亿镰状细胞病患者中,超过 66% 生活在非洲。因此,镰状细胞性贫血的高患病率和针对这种疾病治疗的宣传活动不断加强是一些关键的市场驱动因素。
增加镰状细胞性贫血领域的研发也可能促进市场发展。例如,2022 年 5 月,全球血液治疗公司 (GBT) 镰状细胞病 (SCD) 实验性口服疗法 GBT601 的每日多剂量耐受性良好,并在 I 期临床试验中对六名患者显示出有希望的药理学和疗效信号。因此,镰状细胞性贫血患病率的上升、宣传活动的增加以及研发活动的激增等因素预计将推动市场增长。然而,高昂的治疗成本阻碍了市场的增长。
增长动力和挑战:
镰状细胞病(SCD)的治疗方案可分为维持健康和治疗并发症两大类。镰状细胞性贫血具有基于血红蛋白基因独特突变的基因型和表型变异。该病在全球的发病率很高,严重程度也呈上升趋势。根据世界卫生组织的数据,全球约有5%的人口具有抑制镰状细胞性贫血和地中海贫血等血红蛋白疾病的基因。根据美国国家医学图书馆发表的一项关于镰状细胞病的研究,每年有超过30万名婴儿出生时患有严重的血红蛋白疾病;此外,预计到2050年将有40万名新生儿患有镰状细胞病。此外,根据美国血液学会2023年发表的报告,美国患有SCD的人数估计约为7万至10万人。因此,全球不同地区疟疾和镰状细胞病的发病率不断上升,推动了镰状细胞病治疗市场的增长。此外,全球镰状细胞病发病率较高的各国政府正在部署各种战略,通过改善人们获得医疗服务(包括治疗方案)的机会来根除这种疾病。
SCD 治疗的药物疗法包括羟基脲和一些品牌药物。羟基脲被认为是疾病的一线治疗方法,并受到许多医学专家的推荐。然而,全球发展中国家的治疗选择都存在短缺。根据美国血液学会的数据,撒哈拉以南非洲每年约有 30 万名婴儿患有 SCD。尽管世界卫生组织将羟基脲添加到儿童基本药物标准清单中,但许多发展中地区仍然无法获得该药物。此外,这种药物在非洲被认为非常昂贵。用于治疗 SCD 的输血也取决于捐献者的可用性;即使有捐献者,也存在筛查不足导致输血传播感染增加的风险。此外,非洲国家负责改善医疗设施和护理 SCD 患者的公共和私人医疗保健工作者有限。因此,缺乏 SCD 治疗选择阻碍了镰状细胞病治疗市场的增长。
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
镰状细胞病治疗市场:
复合年增长率(2022 - 2030 年)19.1%- 2022 年市场规模
11.6 亿美元 - 2030 年市场规模
46.9 亿美元
市场动态
- 镰状细胞病患病率不断上升
- 提高人们对 SCD 认识的举措不断涌现
- 扩大新药和疫苗研发渠道
- 市场参与者不断增加的战略举措
关键人物;主力;重要一员
- 诺华公司
- 辉瑞公司
- Emmaus 生命科学公司
- 梯瓦制药工业有限公司
- 百时美施贵宝公司
- 西克洛斯
- 迈兰公司
- 泰姬制药有限公司
- 安宝泰
区域概况
- 北美
- 欧洲
- 亚太
- 南美洲和中美洲
- 中东和非洲
市场细分
- 仿制药和原研药
- 口服和肠外
- 直接招标
- 医院药房
- 零售药店
- 网上药店
- 其他的
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
报告细分和范围:
镰状细胞病治疗市场根据治疗、给药途径和分销渠道进行分类。按治疗方式,市场分为仿制药和原研药。按给药途径,镰状细胞病治疗市场分为口服和肠外给药。按分销渠道,镰状细胞病治疗市场分为直接招标、医院药房、零售药房、网上药房和其他。根据地域划分,镰状细胞病治疗市场分为北美(美国、加拿大和墨西哥)、欧洲(法国、德国、意大利、英国、西班牙、比荷卢三国、奥地利和欧洲其他地区)、亚太地区(澳大利亚、中国、日本、印度、韩国、马来西亚、印度尼西亚和亚太地区其他地区)、中东和非洲(沙特阿拉伯、阿联酋、南非、肯尼亚、坦桑尼亚、卢旺达、尼日利亚、加纳、乌干达、安哥拉、喀麦隆、塞内加尔、赞比亚和中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷和南美洲和中美洲其他地区)
节段分析:
根据治疗方法,镰状细胞病治疗市场分为原研药和仿制药。2022 年,原研药部分占据了更大的市场份额。此外,预计该部分在预测期内的复合年增长率将更高。根据给药途径,镰状细胞病治疗市场分为口服和肠外给药。2022 年,口服部分占据了更大的市场份额。此外,预计该部分在预测期内的复合年增长率将更高。口服给药是最理想和最合适的给药途径,因为它具有高患者依从性、非侵入性、最少的无菌限制、成本效益、剂型设计的灵活性以及制造过程的简易性。易于给药和长期成本效益等好处是推动口服药物采用的主要因素。胶囊、片剂和其他口服药物的低制造成本推动了镰状细胞病治疗市场的增长。
按分销渠道,镰状细胞病治疗市场分为直接招标、医院药房、零售药房、在线药房和其他。2022 年,直接招标部分占据了最大的市场份额。然而,在线药房部分预计将在预测期内录得最高的复合年增长率。招标是执行特定任务或以固定金额提供物品的要约。在此招标程序的第一步中,将要求承包商提交密封的施工投标或在特定时限内提供特别计划的服务或产品。印度的电子招标程序旨在确保及时完成政府或特定客户的工作。例如,一些地方可能有特定的采购法规,规定决策方式和接受哪些投标。在线药房是这个时代发展最快的药房之一。在这种开处方模式下,处方是在线生成的。网上药店的优势包括比零售店更优惠的价格,交易量低,方便购买,消费者依从性更高。网上药店提供送货上门的药品,并提供医疗警报和特许药店产品的折扣。在线服务的发展、互联网的使用以及对非处方药自我用药的认识是促进网上药店销售增长的重要因素。有关主要治疗和药物的教育将刺激市场发展。
区域分析:
根据地理位置,镰状细胞病治疗市场分为五个主要区域——北美、欧洲、亚太地区、南美和中美以及中东和非洲。北美市场分析主要集中在三个主要国家——美国、加拿大和墨西哥。2022 年,中东和非洲占据了镰状细胞病治疗市场的最大份额。可支配收入的增加、对有针对性的营养的需求不断增长、对镰状细胞病治疗和补充剂的认识不断提高是推动市场增长的一些主要因素。
尼日利亚的镰状细胞病治疗市场在 2022 年占据了最大的市场份额,并且很可能成为预测期内增长最快的市场。据报道,在尼日利亚,镰状细胞病儿童由于镰状细胞病的身体影响而无法上学,并且学业成绩不佳。根据美国国家医学图书馆发表的一项题为“镰状细胞病的负担”的研究,镰状细胞性贫血影响了尼日利亚每 1,000,000 人中的 20,000 多人。根据美国国家医学图书馆发表的一项题为“镰状细胞病对尼日利亚受影响个体的影响”的研究,尼日利亚被认为是撒哈拉以南非洲镰状细胞性贫血率最高的国家,影响了 2-3% 的人口。根据世界卫生组织和尼日利亚卫生部的数据,该国总人口的 25% 是导致这种遗传疾病的突变基因的携带者。据美国之音发表的《尼日利亚镰状细胞病倡导者敦促当局坚决干预》一文报道,尼日利亚每年约有10万名儿童被诊断出患有镰状细胞病,高达80%的儿童在5岁前死亡。
镰状细胞病治疗市场未来趋势:
扩大新药和疫苗研发渠道
研发新药被视为最佳策略,因此,镰状细胞病药物/疫苗研发渠道日益强大。公私合作正在加速与镰状细胞病治疗相关的研究活动。
下表列出了一些正在临床开发中的SCD药物/疫苗:
镰状细胞病药物/疫苗/化合物正在临床开发中
药品
|
开发人员
|
临床试验阶段
|
因克拉库单抗 | 辉瑞 | 第三阶段 |
体素 | 辉瑞 | 第三阶段 |
GBT021601 | 辉瑞 | 第二阶段 |
PF-07209326 | 辉瑞 | 第二阶段 |
RG6107 | 罗氏 | 第二阶段 |
GSK4172239D | 葛兰素史克 | 第一阶段 |
梁–101 | Beam 治疗公司 | I/II期 |
HGB-206 | Bluebird Bio 公司 | I/II期 |
HGB-210 | Bluebird Bio 公司 | 第三阶段 |
ALXN1820 | 亚历克森 | 第二阶段 |
NCT05714969 | 武田药品工业株式会社 | 阶段 2b |
NCT03997760 | 武田药品工业株式会社 | 第一阶段 |
资料来源:公司网站,Insight Partners 分析
因此,正在临床开发的SCD药物/疫苗数量的增加预计将在未来推动市场增长。
镰状细胞病治疗市场报告范围
报告属性 | 细节 |
---|---|
2022 年市场规模 | 11.6亿美元 |
2030 年的市场规模 | 46.9亿美元 |
全球复合年增长率(2022 - 2030 年) | 19.1% |
历史数据 | 2020-2021 |
预测期 | 2023-2030 |
涵盖的领域 | 按治疗
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
竞争格局和重点公司:
全球镰状细胞病治疗市场中的一些知名参与者包括诺华公司、辉瑞公司、Emmaus Life Sciences Inc、Teva Pharmaceutical Industries Ltd.、百时美施贵宝公司、Siklos、Mylan NV、Taj Pharmaceuticals Limited 和 Apotex。这些公司专注于开发新技术、改进现有产品和扩大地理覆盖范围,以满足全球不断增长的消费者需求并扩大其专业产品组合范围。在全球镰状细胞病治疗市场运营的公司正在实施各种无机和有机战略。下面提到了其中一些:
- 2023年4月,美国FDA授予Editas Medicine, Inc. EDIT-301孤儿药资格,该药物用于治疗镰状细胞性贫血。
- 2022年10月,辉瑞公司完成对Global Blood Therapeutics, Inc.的收购,该公司参与治疗SCD的药物的开发和商业化。
- 2022年2月,Global Blood Therapeutics Inc.获得Oxbryta的营销批准,用于单一疗法或与羟基脲联合治疗成人和儿童患者(12岁及以上)由SCD引起的溶血性贫血。
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The originators segment dominated the sickle cell disease treatment market and accounted for the largest market share in 2022.
The direct tender segment dominated the sickle cell disease treatment market and accounted for the largest market share in 2022.
Based on route of administration, the oral segment took the forefront leaders in the worldwide sickle cell disease market by accounting largest share in 2022 and is expected to continue to do so till the forecast period.
Answer: - Novartis AG, Pfizer Inc, Emmaus Life Sciences Inc, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Siklos, Mylan NV, Taj Pharmaceuticals Limited, and Apotex among others are among the leading companies operating in the sickle cell disease treatment market.
Increasing prevalence of sickle cell disease and government and private sector's initiative to raise awareness about sickle cell disease are the most significant factors responsible for the overall market growth.
Sickle cell disease treatment market is segmented by countries comprising of North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Sickle cell disease (SCD) is the most common inherited blood disorder that affects the red blood cells. Treatments for SCD can relieve pain and help prevent complications related with the disease. SCD is identified with a simple blood test. In addition, SCD can be detected while the baby is in the womb. Diagnostic tests such as amniocentesis and chorionic villus sampling are done before the baby is born, which helps to check the chromosomal or genetic abnormalities in the baby. A bone marrow transplant can cure SCD. The transplant needs a donor who’s healthy, genetic match, such as a sibling. However, only about 18% of people with SCD have a compatible donor. In addition, there are complications and risks involved with a transplant.
The List of Companies - Sickle Cell Disease Treatment Market
- Novartis AG
- Pfizer Inc
- Emmaus Life Sciences Inc
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Company
- Siklos
- Mylan NV
- Taj Pharmaceuticals Limited
- Apotex
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.